Revenue
EPS
EBIT
Revenue is based on 1 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement
Currency: USD
Unlock Free Earnings Estimates
Immuneering | 10-Q: Q3 2024 Earnings Report
Nov 14 05:14
Immuneering | 8-K: Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates - Announced Positive Initial Data, Including Complete and Partial Responses, with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic
Nov 14 05:08
Immuneering | 8-K: Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates - Enrollment progressing well across all arms in the IMM-1-104 Phase 2a Trial, with Initial Data from Multiple Arms Expected in 2H 2024 -
Aug 7 04:16
Immuneering | 10-Q: Q2 2024 Earnings Report
Aug 7 04:14
Read more
Updated: Dec 22, 2024
Buy
Hold
Sell
No Data